PL3746446T3 - Inhibitory PRC2 - Google Patents
Inhibitory PRC2Info
- Publication number
- PL3746446T3 PL3746446T3 PL19710816.0T PL19710816T PL3746446T3 PL 3746446 T3 PL3746446 T3 PL 3746446T3 PL 19710816 T PL19710816 T PL 19710816T PL 3746446 T3 PL3746446 T3 PL 3746446T3
- Authority
- PL
- Poland
- Prior art keywords
- prc2
- inhibitors
- prc2 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624176P | 2018-01-31 | 2018-01-31 | |
| US201862672701P | 2018-05-17 | 2018-05-17 | |
| US201862747736P | 2018-10-19 | 2018-10-19 | |
| PCT/US2019/015677 WO2019152419A1 (en) | 2018-01-31 | 2019-01-29 | Prc2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3746446T3 true PL3746446T3 (pl) | 2022-08-29 |
Family
ID=65763738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22165237.3T PL4043466T3 (pl) | 2018-01-31 | 2019-01-29 | Inhibitory PRC2 |
| PL19710816.0T PL3746446T3 (pl) | 2018-01-31 | 2019-01-29 | Inhibitory PRC2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22165237.3T PL4043466T3 (pl) | 2018-01-31 | 2019-01-29 | Inhibitory PRC2 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US11485738B2 (pl) |
| EP (2) | EP3746446B1 (pl) |
| JP (3) | JP7025556B2 (pl) |
| KR (2) | KR102776492B1 (pl) |
| CN (1) | CN112004816B (pl) |
| AU (2) | AU2019214861B2 (pl) |
| BR (1) | BR112020015583B1 (pl) |
| CA (1) | CA3089639C (pl) |
| DK (2) | DK3746446T3 (pl) |
| ES (2) | ES2991317T3 (pl) |
| FI (1) | FI4043466T3 (pl) |
| HU (2) | HUE069170T2 (pl) |
| IL (2) | IL276156B (pl) |
| MX (2) | MX2020007974A (pl) |
| NZ (1) | NZ766447A (pl) |
| PL (2) | PL4043466T3 (pl) |
| PT (2) | PT3746446T (pl) |
| WO (1) | WO2019152419A1 (pl) |
| ZA (2) | ZA202004453B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| WO2020108590A1 (zh) * | 2018-11-30 | 2020-06-04 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN114269748A (zh) | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
| JP7357146B2 (ja) * | 2019-08-22 | 2023-10-05 | ブルーレイ セラピューティクス （シャンハイ） カンパニー，リミティド | アザヘテロアリール化合物及びその使用 |
| CN113004233B (zh) * | 2019-12-18 | 2022-12-20 | 南京优氟医药科技有限公司 | 一种用于制备prc2抑制剂的化合物、其制备方法和用途 |
| CN114907385B (zh) * | 2021-02-10 | 2026-07-21 | 上海翱路生物医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
| US20240398811A1 (en) * | 2021-09-24 | 2024-12-05 | Oric Pharmaceuticals, Inc. | Prc2 inhibitors for use in treating blood disorders |
| JP2025529443A (ja) * | 2022-09-14 | 2025-09-04 | オリック ファーマシューティカルズ，インク． | Ｐｒｃ２阻害剤の物理形態 |
| GB202216323D0 (en) | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
| WO2024123669A1 (en) * | 2022-12-05 | 2024-06-13 | Oric Pharmaceuticals, Inc. | Treatment of prostate cancer having androgen receptor variants |
| WO2024148008A1 (en) * | 2023-01-03 | 2024-07-11 | Oric Pharmaceuticals, Inc. | Treatment of neuroendocrine prostate cancer |
| WO2024215699A1 (en) * | 2023-04-11 | 2024-10-17 | Oric Pharmaceuticals, Inc. | Treatment of t-cell lymphoma |
| EP4753714A1 (en) * | 2023-08-04 | 2026-06-10 | Oric Pharmaceuticals, Inc. | Treatment of prostate cancer |
| CN122103153A (zh) * | 2026-04-23 | 2026-05-29 | 上海禧耀医药科技有限公司 | 一种喜树碱中间体cd环衍生物的氘代方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| WO2010021381A1 (ja) | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| MX2012012966A (es) | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| CA2853501A1 (en) | 2011-10-27 | 2013-05-02 | Memorial Sloan-Kettering Cancer Center | Methyltransferase inhibitors for treating cancer |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2836216B1 (en) | 2012-04-13 | 2022-06-08 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| US9105490B2 (en) | 2012-09-27 | 2015-08-11 | Taiwan Semiconductor Manufacturing Company, Ltd. | Contact structure of semiconductor device |
| JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| BR112015008480A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | compostos de benzeno substituído |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| RU2015127822A (ru) | 2012-12-13 | 2017-01-16 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Ингибиторы энхансера гомолога 2 белка zeste |
| CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| PL2953941T3 (pl) | 2013-02-11 | 2017-11-30 | Constellation Pharmaceuticals, Inc. | Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania |
| US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| CA2914414A1 (en) | 2013-06-06 | 2014-12-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| CA2917463A1 (en) | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| WO2015077194A1 (en) | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| AU2015225775B2 (en) | 2014-03-07 | 2017-06-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| PL3121175T3 (pl) | 2014-03-17 | 2020-06-01 | Daiichi Sankyo Company, Limited | Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2 |
| AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| MA40848A (fr) | 2014-10-28 | 2021-05-05 | Glaxosmithkline Ip No 2 Ltd | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
| CA2964629A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| BR112017009440A2 (pt) | 2014-11-06 | 2017-12-19 | Dana Farber Cancer Inst Inc | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2016102493A1 (en) | 2014-12-22 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | Imidazopyridine ezh2 inhibitors |
| IL236420A (en) * | 2014-12-23 | 2016-06-30 | Ron Schneider | Methods and systems for producing an enlarged 3D image |
| MX375970B (es) | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| EP3250552B1 (en) | 2015-01-30 | 2019-03-27 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| US20180037568A1 (en) | 2015-02-13 | 2018-02-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| SI3378859T1 (sl) | 2015-11-19 | 2020-03-31 | Jiangsu Hengrui Medicine Co., Ltd., | Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini |
| EP3386513A2 (en) | 2015-12-07 | 2018-10-17 | Epizyme Inc | Inhibitors of ezh2 and methods of use thereof |
| WO2017174023A1 (zh) | 2016-04-08 | 2017-10-12 | 南京明德新药研发股份有限公司 | 作为ezh2抑制剂的联苯化合物 |
| WO2017184999A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US9957274B2 (en) | 2016-05-06 | 2018-05-01 | Abbvie Inc. | Indane inhibitors of EED and methods of their use |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| JP2019524872A (ja) * | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2019062435A1 (zh) | 2017-09-28 | 2019-04-04 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
| CN109942556A (zh) | 2017-12-21 | 2019-06-28 | 上海青煜医药科技有限公司 | 嘧啶酮化合物及其应用 |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| CN110156787B (zh) | 2018-02-13 | 2021-11-02 | 中国科学院上海药物研究所 | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 |
| CN110563722A (zh) | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN114269748A (zh) | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
-
2019
- 2019-01-29 DK DK19710816.0T patent/DK3746446T3/da active
- 2019-01-29 HU HUE22165237A patent/HUE069170T2/hu unknown
- 2019-01-29 KR KR1020227034197A patent/KR102776492B1/ko active Active
- 2019-01-29 PT PT197108160T patent/PT3746446T/pt unknown
- 2019-01-29 MX MX2020007974A patent/MX2020007974A/es unknown
- 2019-01-29 EP EP19710816.0A patent/EP3746446B1/en active Active
- 2019-01-29 ES ES22165237T patent/ES2991317T3/es active Active
- 2019-01-29 CA CA3089639A patent/CA3089639C/en active Active
- 2019-01-29 AU AU2019214861A patent/AU2019214861B2/en active Active
- 2019-01-29 HU HUE19710816A patent/HUE059536T2/hu unknown
- 2019-01-29 DK DK22165237.3T patent/DK4043466T3/da active
- 2019-01-29 US US16/966,708 patent/US11485738B2/en active Active
- 2019-01-29 CN CN201980011176.8A patent/CN112004816B/zh active Active
- 2019-01-29 PL PL22165237.3T patent/PL4043466T3/pl unknown
- 2019-01-29 BR BR112020015583-7A patent/BR112020015583B1/pt active IP Right Grant
- 2019-01-29 ES ES19710816T patent/ES2923290T3/es active Active
- 2019-01-29 JP JP2020541557A patent/JP7025556B2/ja active Active
- 2019-01-29 FI FIEP22165237.3T patent/FI4043466T3/fi active
- 2019-01-29 EP EP22165237.3A patent/EP4043466B1/en active Active
- 2019-01-29 WO PCT/US2019/015677 patent/WO2019152419A1/en not_active Ceased
- 2019-01-29 KR KR1020207024436A patent/KR102451529B1/ko active Active
- 2019-01-29 PL PL19710816.0T patent/PL3746446T3/pl unknown
- 2019-01-29 NZ NZ766447A patent/NZ766447A/en unknown
- 2019-01-29 PT PT221652373T patent/PT4043466T/pt unknown
-
2020
- 2020-07-20 ZA ZA2020/04453A patent/ZA202004453B/en unknown
- 2020-07-20 IL IL276156A patent/IL276156B/en unknown
- 2020-07-29 MX MX2021012501A patent/MX2021012501A/es unknown
- 2020-12-09 US US17/116,270 patent/US11091495B2/en active Active
-
2021
- 2021-03-31 US US17/219,379 patent/US11220509B2/en active Active
- 2021-08-04 IL IL285354A patent/IL285354B/en unknown
- 2021-10-13 ZA ZA2021/07835A patent/ZA202107835B/en unknown
- 2021-11-12 AU AU2021266351A patent/AU2021266351B2/en active Active
-
2022
- 2022-02-10 JP JP2022019319A patent/JP7288527B2/ja active Active
- 2022-08-26 US US17/822,667 patent/US12371435B2/en active Active
-
2023
- 2023-05-26 JP JP2023086866A patent/JP7495555B2/ja active Active
-
2025
- 2025-05-22 US US19/215,627 patent/US20250282787A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107835B (en) | Prc2 inhibitors | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| IL291430A (en) | mcl–1 inhibitors | |
| IL277006A (en) | CD73 inhibitors | |
| IL304348A (en) | cd73 inhibitors | |
| ZA201905811B (en) | Novel inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| SG11202010347XA (en) | Stat3 inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors |